Sun gets US nod to sell Alzheimer treatment drug
Sun Pharmaceutical Industries today said it has received an approval from the US health regulator to sell generic drug galantamine hydrobromide used in treating mild to moderate Alzheimer's disease, in the American market.
"The US Food and Drug Administration has granted its (Sun's) subsidiary an approval for an abbreviated new drug application (ANDA) to market a generic version of Razadyne ER, galantamine hydrobromide extended-release capsules," the company said in a statement.
Razadyne ER is a registered trademark of Ortho-McNeil Janssen Pharmaceuticals and has an annual sale of around $50 million in the US, it said
The approvals are for multiple strengths of extended-release capsules, 8 mg (base), 16 mg (base) and 24 mg (base), the company added.
Sun Pharmaceutical Industries scrips today closed at Rs 440 on the Bombay Stock Exchange, up nearly 1% from the previous close.